title: Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
abstract: OBJECTIVE
  The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD).
  
  
  METHODS
  In a double blind placebo-controlled clinical trial, the efficacy of 8 mg/day of reboxetine (twice daily) was compared with placebo in 40 adults diagnosed with ADHD during 6 weeks. The measures were Conners' Adult ADHD Rating Scale-Self-Report, Screening Version (CAARS-S, SV), Hamilton Anxiety and Depression Rating Scales, Clinical Global Impression - Severity Scale (CGI-S), and Global Assessment of Functioning Scale (GAF).
  
  
  RESULTS
  There was a main effect of time and significant time X treatment (reboxetine vs. placebo) interaction on CAARS subscales and CGI scores which decreased along the study (p < 0.01). There was also a main effect of time and time X treatment interaction on GAF score which increased at the end point of the study (p < 0.01). In terms of Hamilton Anxiety and Depression Rating Scales there was just a main effect of time on Hamilton Depression Scale (p < 0.01). Irritability, anxiety, sleep disturbance, and dry mouth were the common side effects of reboxetine.
  
  
  CONCLUSIONS
  Reboxetine could be used and tolerated as an effective treatment for adults with ADHD.
authors.affiliation: Department of Psychiatry, Jondi Shapour University, Ahvaz, Iran.
authors.forename: Forough
authors.initials: F
authors.lastname: Riahi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Tehrani-Doost
authors.forename: Zahra
authors.initials: Z
authors.lastname: Shahrivar
authors.forename: Javad
authors.initials: J
authors.lastname: Alaghband-Rad
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D000077593:Reboxetine; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D009025:Morpholines; D010919:Placebos; D000077593:Reboxetine